Canada · Venture startup

Who invested in Paradox Immunotherapeutics

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$10Mraised across 1 round since 2025, from 1 source

Latest round
Venture, $10MFeb 2025
Investors
1
See who backed them

The rounds

  1. Feb 2025
    Venture$10M

    Source recorded

Founders and team

From Paradox Immunotherapeutics's own website: 2 founders, 2 on the team.

Natalie J. GalantCo-Founder of Paradox Immunotherapeutics
Yulong SunCo-Founder of Paradox Immunotherapeutics
  • Sandy ZweifachExecutive Chairman
  • Strategic AdvisorDirector

AdvisersHoward MayerMedical Scientist

Everyone who backed them

Creative Destruction LabAccelerator1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Paradox Immunotherapeutics

Who invested in Paradox Immunotherapeutics?

Paradox Immunotherapeutics's investors include Creative Destruction Lab.

How much has Paradox Immunotherapeutics raised?

Paradox Immunotherapeutics has raised $10M across 1 round since 2025.

When did Paradox Immunotherapeutics last raise?

Paradox Immunotherapeutics's most recent round was a Venture of $10M in Feb 2025.

What was Paradox Immunotherapeutics's biggest round?

Its most recent round, $10M in Feb 2025, is also its largest on record.

Who backed Paradox Immunotherapeutics first?

Paradox Immunotherapeutics's first round on record, in Feb 2025, was backed by Creative Destruction Lab.

What stage is Paradox Immunotherapeutics at?

Paradox Immunotherapeutics's latest named round is a Venture, in Feb 2025.

Where is Paradox Immunotherapeutics based?

Paradox Immunotherapeutics is based in Canada.

Companies like Paradox Immunotherapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.